Jan‐Stefan van der Walt

Author

Also Known As

J Van Der Walt, J Van der Walt, J Walt, J. Van Der Walt, Jan-Stefan Van Der Walt, Jan-Stefan Van der Walt, Jan-Stefan van der Walt, Jan‐Stefan Van Der Walt, Jan‐Stefan van der Walt

Publications

773

Citations

H-Index

Concepts

All Affiliations

Uppsala University University of Cape Town Eli Lilly (United Kingdom)Astellas Pharma (Japan)Astellas Pharma (Netherlands)

About

Jan‐Stefan van der Walt is an author at Uppsala University specializing in medicine, pharmacokinetics, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	68
2	Health Sciences	1	1	12
3	Biostatistics	1	1	12
4	Diabetes	1	1	12
5	Endocrinology	1	1	12

Jan‐Stefan van der Walt

Publications

636

Citations

H-Index

Page 1

	Year	Citations
Pharmacokinetic Drug Interaction Studies with Enzalutamide Jacqueline A. Gibbons, Michiel S. de Vries, Walter Krauwinkel, Clinical Pharmacokinetics	2015	153
Clinical Pharmacokinetic Studies of Enzalutamide Jacqueline A. Gibbons, Taoufik Ouatas, Walter Krauwinkel, Clinical Pharmacokinetics	2015	132
Pharmacokinetics and Safety of Extemporaneously Compounded Valacyclovir Oral Suspension in Pediatric Patients from 1 Month through 11 Years of Age David W. Kimberlin, Richard F. Jacobs, S Weller, Clinical Infectious Diseases	2009	60
Population Pharmacokinetics of Ethambutol in South African Tuberculosis Patients Siv Jönsson, Alistair Davidse, Justin Wilkins, Antimicrobial Agents and Chemotherapy	2011	50
Effects of Four Different Meal Types on the Population Pharmacokinetics of Single-Dose Rifapentine in Healthy Male Volunteers Simbarashe Zvada, Jan‐Stefan van der Walt, Peter J. Smith, Antimicrobial Agents and Chemotherapy NutritionPharmacokinetic ModelingMedicineTuberculosisRifapentine Exposure	2010	43
A Quantitative Systems Pharmacology Consortium Approach to Managing Immunogenicity of Therapeutic Proteins Andrzej Kierzek, Timothy P. Hickling, Isabel Figueroa, CPT Pharmacometrics & Systems Pharmacology	2019	30
Japanese subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as initial therapy for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer Masato Takahashi, Eriko Tokunaga, Joji Mori, Breast Cancer	2021	30
Population Pharmacokinetics of Lopinavir and Ritonavir in Combination with Rifampicin-Based Antitubercular Treatment in HIV-Infected Children Chao Zhang, Helen McIlleron, Yuan Ren, Antiviral Therapy	2011	29
Integration of data from multiple sources for simultaneous modelling analysis: experience from nevirapine population pharmacokinetics Elin M. Svensson, Jan‐Stefan van der Walt, Karen I. Barnes, British Journal of Clinical Pharmacology	2012	28
Japanese subpopulation analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapy Kenichi Inoue, Norikazu Masuda, Hiroji Iwata, Breast Cancer	2021	24

Page 1